Verdiva Bio
Leo Seman currently serves as Vice President of Clinical Development at Verdiva Bio, where responsibilities include developing study design strategies for a cardiometabolic portfolio and designing clinical trials to meet critical data needs. Previous experience includes roles as Executive Director of Clinical Development at Structure Therapeutics and Medical Expert in Clinical Development Medical Affairs at Boehringer Ingelheim, focusing on cardiometabolism. Additionally, Leo held director positions at Bayer Pharmaceuticals in Metabolics and worked as Global Project Leader for Diabetes at USDA HNRCA. Academic qualifications include a Fellowship in Endocrinology and Nutrition from Tufts University School of Medicine, an Internal Medicine Residency from Wake Forest University School of Medicine, an MD/PhD in Medicine/Biochemistry from Dalhousie University, and a BA in Chemistry from the College of the Holy Cross.
This person is not in the org chart
This person is not in any offices
Verdiva Bio
1 followers
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.